Wei, Yan http://orcid.org/0000-0002-2682-3780
Chang, Lijia
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0107119)
National Natural Science Foundation of China (31701009)
Article History
Received: 8 February 2021
Revised: 1 April 2021
Accepted: 13 April 2021
First Online: 7 May 2021
Compliance with ethical standards
:
: KH is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, and “TGF-β1 in the treatment of depression” by the Chiba University. KH also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, and Taisho. The other authors have no conflict of interest.